CagriSema: Cagrilintide + Semaglutide Combination Research and the Amylin-GLP-1 Dual Pathway

Introduction

CagriSema is an investigational fixed-dose combination peptide therapy developed by Novo Nordisk, combining cagrilintide 2.4 mg (a long-acting amylin analogue) with semaglutide 2.4 mg (a GLP-1 receptor agonist) in a single weekly subcutaneous injection. Filed for FDA approval in December 2025, CagriSema represents a novel approach to metabolic research that targets two distinct but complementary hormonal pathways -- the amylinergic and incretin systems -- simultaneously [1].

The rationale for combining these two peptide classes stems from the observation that amylin and GLP-1 act through different but synergistic neural circuits to regulate appetite and energy balance. While GLP-1 receptor agonists have demonstrated substantial efficacy in weight reduction research, the addition of amylin receptor agonism is hypothesized to produce additive effects through independent satiety signaling pathways, potentially achieving greater weight loss than either compound alone [2].

Component Peptides: Molecular Profiles

Cagrilintide is a synthetic long-acting analogue of amylin (islet amyloid polypeptide, IAPP), a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells. Native amylin has a plasma half-life of only a few minutes; cagrilintide's structural modifications -- including fatty acid conjugation -- extend its half-life to approximately 7 days, enabling once-weekly dosing. Amylin receptors (AMY1-3) are expressed in the area postrema and nucleus tractus solitarius of the brainstem, regions distinct from the primary sites of GLP-1R expression, providing the mechanistic basis for independent and potentially additive satiety signaling [3].

Semaglutide in the CagriSema formulation is identical in structure to the approved semaglutide 2.4 mg (Wegovy) -- a 31-amino acid GLP-1 analogue with a C18 fatty diacid chain providing albumin binding and a ~7-day half-life. Its mechanism of action through GLP-1R activation in hypothalamic circuits, brainstem nuclei, and peripheral tissues is well-characterized in the research literature [4].

| Component | Class | Receptor Target | Half-Life | Dose in CagriSema | |---|---|---|---|---| | Cagrilintide | Amylin analogue | AMY1, AMY2, AMY3 | ~7 days | 2.4 mg weekly | | Semaglutide | GLP-1 analogue | GLP-1R | ~7 days | 2.4 mg weekly |

REDEFINE Phase 3 Program: Key Findings

The REDEFINE Phase 3 program evaluated CagriSema in adults with obesity across multiple trials, with results reported in 2025.

REDEFINE-1 enrolled 3,417 adults without type 2 diabetes. Published in the New England Journal of Medicine (June 2025), the trial demonstrated that CagriSema produced a mean body weight reduction of 22.7% over 68 weeks, compared to 8.0% for cagrilintide alone and 15.7% for semaglutide alone -- providing direct evidence for the additive effect of combining amylin and GLP-1 receptor agonism [5]. The combination achieved statistically significant superiority over semaglutide monotherapy (p<0.001).

REDEFINE-2 evaluated CagriSema in adults with type 2 diabetes and obesity. Results showed CagriSema achieved superior HbA1c reduction of 1.91 percentage points compared to 1.76 percentage points with semaglutide alone, alongside greater body weight reductions [6]. The combination outperformed semaglutide monotherapy with weight loss of 14.2% versus semaglutide's 10.2% -- a statistically significant difference that nonetheless fell short of Novo Nordisk's internal target of 25% reduction, highlighting the challenges of achieving retatrutide-comparable weight loss in the type 2 diabetes population [7].

Mechanism of Action: Dual Pathway Satiety Research

The mechanistic basis for CagriSema's enhanced efficacy relative to semaglutide monotherapy is an active area of research investigation. Current evidence suggests the combination engages complementary but non-overlapping neural circuits:

Amylin pathway (cagrilintide): Amylin receptor activation in the area postrema and nucleus tractus solitarius reduces meal size and prolongs the inter-meal interval through mechanisms distinct from GLP-1R signaling. Preclinical studies demonstrate that amylin reduces food intake primarily by reducing meal size, while GLP-1 reduces both meal size and meal frequency, suggesting complementary temporal profiles of satiety signaling [8].

GLP-1 pathway (semaglutide): GLP-1R activation in the hypothalamus (particularly the arcuate nucleus and paraventricular nucleus) reduces neuropeptide Y (NPY) and agouti-related peptide (AgRP) expression while increasing pro-opiomelanocortin (POMC) activity -- the classical anorexigenic pathway. GLP-1R activation also modulates dopaminergic reward circuits, potentially reducing hedonic eating [9].

In combination, preclinical models demonstrate that amylin and GLP-1 receptor co-activation produces greater reductions in body weight and adiposity than either agent alone at equivalent doses, with some studies suggesting synergistic rather than merely additive effects in specific metabolic parameters [2].

Research Applications

CagriSema provides researchers with a tool for studying the intersection of amylinergic and incretin signaling in metabolic disease models. Its fixed-dose combination format enables investigation of dual-pathway satiety mechanisms without the confounds of separate dosing schedules. Key research applications include studies examining the relative contributions of amylin versus GLP-1 signaling to weight loss using selective receptor antagonists to dissect pathway-specific contributions.

The REDEFINE program data also enables researchers to model the dose-response relationship between multi-pathway hormonal engagement and metabolic outcomes, informing the design of next-generation combination peptide therapies. The FDA filing by Novo Nordisk in December 2025 signals that CagriSema may become a clinically approved reference compound in 2026 or 2027, making current preclinical and early clinical research particularly valuable for establishing baseline mechanistic understanding [1].

This article is intended for scientific and educational reference within a laboratory research context only. All products sold by Pure Pharm Peptides are for research use only and are not intended for human or animal consumption.

References

1. PR Newswire. (December 2025). Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management.
2. Clemmensen, C., et al. (2014). Amylin and GLP-1 synergistically reduce food intake. Molecular Metabolism, 3(5), 553-558.
3. Hay, D.L., et al. (2015). Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews, 67(3), 564-600.
4. Drucker, D.J. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 27(4), 740-756.
5. NEJM. (June 2025). Coadministered Cagrilintide and Semaglutide in Adults with Obesity. New England Journal of Medicine, 392(26).
6. Clinical Trials Arena. (February 2026). Novo Nordisk's CagriSema outperforms Ozempic in Phase III trial. clinicaltrialsarena.com.
7. Fierce Biotech. (February 2026). Novo's CagriSema tops semaglutide in ph. 3 diabetes study, still falls short of 25% weight loss goal.
8. Lutz, T.A. (2012). Control of energy homeostasis by amylin. Cellular and Molecular Life Sciences, 69(12), 1947-1965.
9. Gabery, S., et al. (2020). Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight, 5(6), e133429.